Please login to the form below

Not currently logged in
Email:
Password:

risk-sharing agreements

This page shows the latest risk-sharing agreements news and features for those working in and with pharma, biotech and healthcare.

Friend or foe?

Friend or foe?

The first was about Express Scripts, a US pharmacy benefits manager, demanding risk-sharing price arrangements from pharma companies. ... In more sophisticated examples, the uncertainty that each side faces is mitigated by risk-sharing agreements.

Latest news

  • Pharma industry must listen to pharmacies Pharma industry must listen to pharmacies

    This is especially true given that risk-sharing agreements could potentially see companies lose money, Dr Alessi acknowledged.

  • Emerging business models for pharma Emerging business models for pharma

    The precursors to such networks are well-established ideas like joint ventures, outsourcing relationships and risk-sharing agreements, but pharma holobionts appear to evolving well beyond these relatively primitive arrangements in ... Cultures vary

  • Model behaviour in proactive and reactive pharma markets Model behaviour in proactive and reactive pharma markets

    health technology assessments, risk-sharing and real-world evidence (RWE). ... Companies should also continue to propose outcome-based agreements (OBA), despite risk-sharing having become mostly about discounting and fallen into the Trough of

  • Just des(s)erts - choices for payers in times of austerity

    AIFA has in the past rewarded innovation with high prices, while controlling expenditure through risk-sharing agreements. ... However, it appears that the true savings from risk-sharing agreements are far less than anticipated, because refunds are

  • Industry 'should work closer with payers on drug development'

    felt that the sector should absorb more risk to improve biopharmaceutical agents and the public health. ... agreeing that risk-sharing agreements between biopharmaceutical companies and payers would lead to more innovative and effective therapies.

More from news
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • No incentive for a cure No incentive for a cure

    However, there is the question of risk. We still do not really know the long-term effects of most of these medicines. ... Incremental changes may work in the short-term. Incremental changes include solutions such as outcome-based/value-based reimbursement

  • Market access improvements in Turkey Market access improvements in Turkey

    Such models are already found in several European countries and indeed worldwide, and are generally known as managed entry or risk-sharing agreements.

  • Pharma–payer partnerships – rhetoric or reality? Pharma–payer partnerships – rhetoric or reality?

    Payer partnerships fall into two categories: price and reimbursement (risk-sharing agreements/patient access schemes) and value add (provision of services beyond the pill). ... more value to the industry than to payers (Raftery J, BMJ 2010; 340:c1672

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

We are industry-leading thinkers when it comes to education. We use the latest academic thinking on the psychology of behaviour...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics